The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only improved invasive-free survival in women with this type of early-stage ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Penelope Oliver, a volunteer with Students Demand Action in California, talks to Hal about state laws involving firearms.

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recent clinical trial data suggested a new first-line ...

Revenue: Revenue was $0 for the third quarter of 2024, as compared to $25.2 million for the third quarter of 2023. The decrease was primarily due to the recognition of previously received milestone ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Relay Therapeutics (RLAY – Research Report), retaining the price ...

Get detailed information on Ribociclib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...